Search

Your search keyword '"Daratumumab"' showing total 140 results
Start Over Descriptor "Daratumumab" Publisher syndigate media inc.
140 results on '"Daratumumab"'

5. Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology

Subjects
United States. Food and Drug Administration, Pomalidomide, Multiple myeloma -- Care and treatment, Daratumumab, Drug approval, Dexamethasone -- Product development, Business, international, Law
Abstract

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating [...]

Published
2020

7. Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Subjects
United States. Food and Drug Administration, Genmab A/S, Hyaluronidase, Small cell lung cancer, Epidermal growth factors, Daratumumab, Pharmaceutical industry, Drug approval, Ofatumumab, Non-small cell lung cancer, Business, international, Law
Abstract

(GlobeNewswire) - Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor [...]

Published
2020

8. Amgen Announces New Data Being Presented At ASH 2020

Subjects
Carfilzomib, Blinatumomab, Daratumumab, T cells, Business, international, Law
Abstract

Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, [...]

Published
2020

9. Pomalidomide

Subjects
Pomalidomide, Daratumumab, Business, international
Abstract

Contract Awarded for Pomalidomide Title : Pomalidomida daratumumab Quantity: 21.00 COMPRIMIDO Unit Price without taxes: $ 16.311,90 Contractor name : NOLVER S A (RUT 211455890011) Contractor address : Uruguay Implementing [...]

Published
2020

10. Daratumumab

Subjects
Daratumumab, Business, international
Abstract

Contract Awarded for Daratumumab Title : Pomalidomida daratumumab Quantity: 4.00 AMPOLLA Unit Price without taxes: $ 20.407,50 Contractor name : JOHNSON Y JOHNSON DE URUGUAY S A (RUT 210730630013) Contractor [...]

Published
2020

11. Daratumumab

Subjects
Daratumumab, Business, international
Abstract

Contract notice: Daratumumab Specification of goods and expected consumption: Medicinal product with active substance Daratumumab, ATC group L01XC24 Estimated quantity of goods taken over four years: - 11 000 original [...]

Published
2020

12. Procurement Inj. Daratumumab 400mg

Subjects
Purchasing, Daratumumab, Business, international
Abstract

Tenders are invited for Procurement inj. Daratumumab 400mg Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 Location: Aiims, new delhi Document Download Start [...]

Published
2020

13. Especially Expensive Drug Daratumumab

Subjects
Daratumumab, Business, international
Abstract

Contract notice: Especially expensive drug daratumumab Especially expensive drug Daratumumab. This contract is divided into lots: no Conditions for opening tenders Date: 17/12/2020Local time: 11:00 Health Major organization : KLINICKA [...]

Published
2020

14. Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Subjects
ADC Therapeutics S.A. -- Licensing agreements, Genmab A/S -- Licensing agreements, Hyaluronidase -- Licensing agreements, Biopharmaceuticals -- Licensing agreements, Pembrolizumab, Daratumumab, Pharmaceutical industry -- Licensing agreements, Ofatumumab -- Licensing agreements, Company licensing agreement, Business, international, Law
Abstract

(GlobeNewswire) - Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020 ADC Therapeutics to continue the development and commercialization of Cami Genmab to receive mid-to-high single-digit tiered royalty Genmab [...]

Published
2020

15. Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

Subjects
Cells (Biology), Daratumumab, Radiation (Physics), Business, international, Law
Abstract

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ('Actinium' or the 'Company') today announced the launch of its new research and development lab facility in New York City. This new research facility [...]

Published
2020

16. Melflufen Open to Select Adults With Advanced Multiple Myeloma in US

Subjects
United States. Food and Drug Administration, Pomalidomide, Multiple myeloma -- Care and treatment, Daratumumab, Adults, Business, international, Law
Abstract

Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with triple-refractory multiple myeloma to access the investigational medicine melflufen (melphalan flufenamide) before its approval. sEAPort (NCT04534322) is [...]

Published
2020

17. Grant of Restricted Stock Units and Warrants to Employees in Genmab

Subjects
Genmab A/S, Hyaluronidase, Stocks, Daratumumab, Pharmaceutical industry, Ofatumumab, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; October 7, 2020 Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 14,187 restricted stock units and [...]

Published
2020

18. Grant of Restricted Stock Units and Warrants to Employees in Genmab

Subjects
Genmab A/S, Hyaluronidase, Stocks, Daratumumab, Pharmaceutical industry, Ofatumumab, Business, international, Law
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; October 7, 2020 Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 14,187 restricted stock units and [...]

Published
2020

19. Procurement Of Inj. Daratumumab 100mg

Subjects
Purchasing, Daratumumab, Business, international
Abstract

Tenders are invited for Procurement of inj. Daratumumab 100mg Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 Location: Aiims, new delhi Document Download [...]

Published
2020

20. Transactions with shares and linked securities in Genmab A|S made by managerial employees and their closely associated persons

Subjects
Novartis AG, Genmab A/S, Workers, Hyaluronidase, Stocks, Daratumumab, Pharmaceutical industry, Ofatumumab, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; September 29, 2020 In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data [...]

Published
2020

21. Transactions with shares and linked securities in Genmab A|S made by managerial employees and their closely associated persons

Subjects
Novartis AG, Genmab A/S, Workers, Hyaluronidase, Stocks, Daratumumab, Pharmaceutical industry, Ofatumumab, Business, international, Law
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; September 29, 2020 In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data [...]

Published
2020

22. Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen

Subjects
Genmab A/S -- Negotiation, mediation and arbitration -- Licensing agreements, Hyaluronidase -- Licensing agreements, Daratumumab, Ofatumumab -- Licensing agreements, Company licensing agreement, Telecommunications industry, Darzalex (Medication) -- Licensing agreements
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; September 22, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with [...]

Published
2020

23. Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen

Subjects
Genmab A/S -- Negotiation, mediation and arbitration -- Licensing agreements, Hyaluronidase -- Licensing agreements, Daratumumab, Ofatumumab -- Licensing agreements, Company licensing agreement, Business, international, Law, Darzalex (Medication) -- Licensing agreements
Abstract

(GlobeNewswire) - Company Announcement Copenhagen, Denmark; September 22, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with [...]

Published
2020

24. Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Amyloidosis -- Drug therapy, Hyaluronidase, Daratumumab, Pharmaceutical industry, Drug approval, Business, international, Law, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of [...]

Published
2020

25. Janssen files for FDA approval of Darzalex Faspro

Subjects
United States. Food and Drug Administration, Amyloidosis, Hyaluronidase, Daratumumab, Drug approval, Business, international, Law, Darzalex (Medication)
Abstract

Janssen Pharmaceutical has filed an application with the US Food and Drug Administration (FDA) seeking approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat light chain (AL) amyloidosis. Janssen Pharmaceutical [...]

Published
2020

26. United States : Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Amyloidosis -- Drug therapy, Hyaluronidase, Daratumumab, Pharmaceutical industry, Drug approval, Business, international, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX [...]

Published
2020

27. Daratumumab

Subjects
Daratumumab, Business, international
Abstract

Contract Awarded for Daratumumab Title : Daratumumab Quantity: 6.00 AMPOLLA Unit Price without taxes: $ 81.630,00 Contractor name : JOHNSON Y JOHNSON DE URUGUAY S A Contractor address : Uruguay [...]

Published
2020

28. Procurement Of Inj. Daratumumab 100mg|20ml

Subjects
Purchasing, Daratumumab, Business, international
Abstract

Tenders are invited for Procurement of inj. Daratumumab 100mg/20ml Product Category: Miscellaneous goods Tender Type: Open tender Bid Validity(Days): 30 Period Of Work(Days): 45 Location: Aiims, new delhi Document Download [...]

Published
2020

29. United States : FDA Approves New KYPROLIS (carfilzomib) Combination Regimen With DARZALEX (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens

Subjects
United States. Food and Drug Administration, Carfilzomib, Central nervous system depressants, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Dexamethasone, Business, international, Darzalex (Medication)
Abstract

Amgen announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX (daratumumab) plus [...]

Published
2020

30. FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma

Subjects
United States. Food and Drug Administration, Carfilzomib, Multiple myeloma, Daratumumab, Drug approval, Dexamethasone, Business, international, Law, Darzalex (Medication)
Abstract

The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Kyprolis (carfilzomib) and dexamethasone, to treat adults with relapsed or refractory multiple myeloma after one to [...]

Published
2020

31. Ligand Announces Amgens KYPROLIS Approved by FDA as Combination Regimen with DARZALEX and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed|Refractory Multiple Myeloma

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Carfilzomib, Recurrence (Disease) -- Drug therapy, Central nervous system depressants, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Dexamethasone, Business, international, Law, Darzalex (Medication)
Abstract

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the KYPROLIS (carfilzomib) [...]

Published
2020

32. FDA Approves New KYPROLIS (carfilzomib) Combination Regimen With DARZALEX (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens

Subjects
United States. Food and Drug Administration, Carfilzomib, Central nervous system depressants, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Dexamethasone, Business, international, Law, Darzalex (Medication)
Abstract

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX [...]

Published
2020

33. Daratumumab Sol Inj Fr 5 And 20 Ml

Subjects
Daratumumab, Business, international
Abstract

Contract awarded for Daratumumab sol inj fr 5 and 20 ml Date of conclusion of the contract: 30-06-2020 Contract price: 67. 463,16 Deadline: 20 days Place of execution - Country, [...]

Published
2020

34. Daratumumab Sol. Inj. Fr 5 And 20 Ml

Subjects
Daratumumab, Business, international
Abstract

Contract awarded for Daratumumab sol. Inj. Fr 5 and 20 ml Date of conclusion of the contract: 30-06-2020 Contract price: 134. 926,32 Deadline: 20 days Place of execution - Country, [...]

Published
2020

35. United States : U.S. FDA Approves New DARZALEX (daratumumab)-Based Combination Regimen for Patients with Relapsed|Refractory Multiple Myeloma

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Carfilzomib, Recurrence (Disease) -- Drug therapy, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Pharmaceutical industry, Business, international, Darzalex (Medication)
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of DARZALEX (daratumumab) in combination with Kyprolis (carfilzomib) and dexamethasone (DKd) for the [...]

Published
2020

36. U.S. FDA Approves Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis

Subjects
United States. Food and Drug Administration, Novartis Pharma AG, Genmab A/S, Hyaluronidase, Daratumumab, Pharmaceutical industry, Drug approval, Multiple sclerosis -- Drug therapy, Ofatumumab, Teriflunomide, Business, international
Abstract

(GlobeNewswire) - Company Announcement Kesimpta (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adults First B-cell therapy that can be self-administered using Sensoready [...]

Published
2020

37. U.S. FDA Approves Kesimpta (ofatumumab) in Relapsing Multiple Sclerosis

Subjects
United States. Food and Drug Administration, Novartis Pharma AG, Genmab A/S, Hyaluronidase, Daratumumab, Pharmaceutical industry, Drug approval, Multiple sclerosis -- Drug therapy, Ofatumumab, Teriflunomide, Business, international, Law
Abstract

(GlobeNewswire) - Company Announcement Kesimpta (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adults First B-cell therapy that can be self-administered using Sensoready [...]

Published
2020

38. Autolus CMO Peddareddigari departs to return to the US

Subjects
Johnson & Johnson, Daratumumab, Pharmaceutical industry, T cells, Business, international, Law
Abstract

Autolus chief medical officer (CMO) Vijay Peddareddigari is leaving the company to return to the U.S. The British CAR-T biotech disclosed the departure alongside news that Nushmia Khokhar, who crossed [...]

Published
2020

39. Daratumumab

Subjects
Daratumumab, Business, international
Abstract

Contract Awarded for Daratumumab Title : Daratumumab Quantity: 2.00 AMPOLLA Unit Price without taxes: $ 20.407,50 Contractor name : JOHNSON Y JOHNSON DE URUGUAY S A (RUT 210730630013) Contractor address [...]

Published
2020

40. Autolus announces changes to its Board and Management Team

Subjects
Celgene Corp. -- Officials and employees, Daratumumab, Pharmaceutical industry -- Officials and employees, T cells, Business, international, Law
Abstract

(GlobeNewswire) - Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, [...]

Published
2020

41. Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Multiple Myeloma

Subjects
Patient advocacy, Cancer treatment, Elotuzumab, Cancer -- Drug therapy, Immunotherapy, Daratumumab, Associations, Business, international, Law
Abstract

(PRWeb) - The Society for Immunotherapy of Cancer (SITC), the worlds leading member-driven organization dedicated solely to cancer immunotherapy, has published a clinical practice guideline specific to the use of [...]

Published
2020

42. Daratumumab 20 Mg|Ml Sol Inj Fr 5 Ml Iv

Subjects
Daratumumab, Business, international
Abstract

Contract awarded for Daratumumab 20 mg / ml sol inj fr 5 ml iv Date of conclusion of the contract: 10-07-2020 Contract price: 7. 309,20 Deadline: 180 days Place of [...]

Published
2020

43. Amgros 2020-1.863.a

Subjects
Daratumumab, Business, international
Abstract

Contract notice: Amgros 2020-1.863.a. The tender number includes the following medicines: Auction No: 1, ATC Code: L01XC24, Generic name: Daratumumab, Dispensing form: Injection liquid, Strength: 1,800 mg / ml, Unit [...]

Published
2020

44. Belgium : Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Subjects
Johnson & Johnson, Amyloidosis -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Business, international
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumabi in the treatment of patients with newly diagnosed light [...]

Published
2020

46. Daratumumab 20mg

Subjects
Daratumumab, Business, international
Abstract

Contract awarded for Daratumumab 20mg Date of conclusion of the contract: 25-03-2020 Contract price: 29. 967,36 Deadline: 20 days Place of execution - Country, District, Municipality: Portugal, porto, porto Contractor [...]

Published
2020

47. Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Subjects
Johnson & Johnson, Amyloidosis -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Business, international, Law
Abstract

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumabi in the treatment of patients with newly diagnosed light [...]

Published
2020

48. Genmab and AbbVie Announce Broad Oncology Collaboration

Subjects
AbbVie Inc. -- Research agreements, Genmab A/S -- Research agreements, Hyaluronidase, Daratumumab, Pharmaceutical industry -- Research agreements, Biological products, Ofatumumab, Business, international, Law, Darzalex (Medication)
Abstract

(GlobeNewswire) - Company Announcement Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize three of Genmabs next-generation bispecific antibody products, including epcoritamab Companies establish a discovery [...]

Published
2020

49. NICE rejects Sanofi's Sarclisa in preliminary guidelines

Subjects
Sanofi S.A., Pomalidomide, Multiple myeloma, Daratumumab, Pharmaceutical industry, Dexamethasone, Clinical trials, Glucocorticoids, Diseases, Business, international, Law
Abstract

The company proposes that Sarclisa plus pomalidomide and dexamethasone (pom-dex) be used to treat multiple myeloma only in people who have had at least three treatments before. At this stage [...]

Published
2020

50. Daratumumab

Subjects
Daratumumab, Contractors, Business, international
Abstract

Contract Awarded for Daratumumab Title : Daratumumab Quantity: 6.00 AMPOLLA Unit Price without taxes: $ 81.630,00 Contractor name : JOHNSON Y JOHNSON DE URUGUAY S A (RUT 210730630013) Contractor address [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results